California-based AI drug discovery company Atomwise has entered into a strategic multi-target research collaboration with French pharmaceutical company Sanofi to accelerate the development of novel therapeutics across various disease areas.
Under the terms of the partnership, Atomwise will receive an upfront payment of USD 20 million and more than USD 1 billion potentially in milestone payments and tiered royalties.
The partnership will leverage Atomwise’s AI-powered drug discovery platform AtomNet which facilitates the screening of over 3 trillion synthesizable compounds to discover and develop lead compounds for up to five novel drug targets exclusive to Sanofi.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.